美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Loxo Oncology

234.66

0.0000

成交量：- -

成交额：- -

市值：72.17亿

市盈率：-112.40

高：234.66

开：234.66

低：234.66

收：234.66

52周最高：234.93

52周最低：103.50

股本：3,075.46万

流通股本：2,752.00万

量比：- -

换手率：- -

股息：- -

股息率：- -

每股收益(TTM):-2.0877

每股收益(LYR):-5.3102

净资产收益率：--

总资产收益率：--

市净率：19.03

市盈率(LYR):-44.19

数据加载中...

总览公司新闻资讯公告

公司资料

公司名字：

Loxo Oncology

交易所：

NASDAQ

成立时间：

- -

员工人数：

- -

公司地址：

- -

官网：

http://www.loxooncology.com

邮编：

- -

电话：

- -

传真：

- -

简介：

Loxo Oncology, Inc.于2013年5月9号在特拉华州成立。公司开发有针对性的基因定义的患者群体的治疗癌症的小分子疗法。公司的开发方式转换了相关癌症转换成药物，这些药物能够有效的和高选择性的达到关键科学见解的预期目标。这些药物通常能够达到更高的目标任务和改善相关肿瘤的反应。公司识别和优先考虑的目标有两种方式。首先，该公司使用的临床试验数据来评估药物的发展，响应信号和识别那些承诺也证明药物的具体限制，如吸收差，差的分布或有害的副作用。第二，该公司评估学术研究发现新的目标与新兴的验证。一旦确定目标,公司使用先进的第三方技术来开发候选产品旨在增强目标接触和特异性。

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/LOXO/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LOXO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LOXO\",,,,,undefined,":{"symbol":"LOXO","market":"US","secType":"STK","nameCN":"Loxo Oncology","latestPrice":234.66,"timestamp":1557432000000,"preClose":234.66,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":27520039,"shares":30754634,"eps":-2.087713,"marketStatus":"停牌","change":0,"latestTime":"03-20 18:27:15 EDT","open":234.66,"high":234.66,"low":234.66,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.087713,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1774051200000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1406865600000,"exchange":"NASDAQ","adjPreClose":234.66,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LOXO\",,,,,undefined,":{"symbol":"LOXO","floatShares":27520039,"roa":"--","roe":"--","lyrEps":-5.31023,"shares":30754634,"dividePrice":0,"high":234.66,"amplitude":0,"preClose":234.66,"low":234.66,"week52Low":103.5,"pbRate":"19.03","week52High":234.93,"institutionHeld":0,"latestPrice":234.66,"eps":-2.087713,"divideRate":0,"volume":0,"delay":0,"ttmEps":-2.087713,"open":234.66,"prevYearClose":234.66},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LOXO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2018-11-08","symbol":"LOXO","fiscalQuarterEnding":"2018/09","expectedEps":-0.07,"name":null,"time":"盘前","type":"earning","dateTimestamp":1541653200000,"reportTimeType":"pre","actualEps":-2.26},{"market":"US","date":"2018-08-09","symbol":"LOXO","fiscalQuarterEnding":"2018/06","expectedEps":-0.54,"name":null,"time":"盘前","type":"earning","dateTimestamp":1533787200000,"reportTimeType":"pre","actualEps":-0.39},{"market":"US","date":"2018-05-08","symbol":"LOXO","fiscalQuarterEnding":"2018/03","expectedEps":-0.6,"name":null,"time":"盘前","type":"earning","dateTimestamp":1525752000000,"reportTimeType":"pre","actualEps":-0.12},{"market":"US","date":"2018-03-01","symbol":"LOXO","fiscalQuarterEnding":"2017/12","expectedEps":-1.22,"name":null,"time":"盘前","type":"earning","dateTimestamp":1519880400000,"reportTimeType":"pre","actualEps":-0.69},{"market":"US","date":"2017-11-02","symbol":"LOXO","fiscalQuarterEnding":"2017/09","expectedEps":-1.38,"name":null,"time":"盘前","type":"earning","dateTimestamp":1509595200000,"reportTimeType":"pre","actualEps":-1.12}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LOXO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LOXO\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.loxooncology.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":-0.0338},{"period":"3month","weight":-0.0305},{"period":"6month","weight":-0.0059},{"period":"1year","weight":0.1634},{"period":"ytd","weight":-0.0324}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Loxo Oncology, Inc.于2013年5月9号在特拉华州成立。公司开发有针对性的基因定义的患者群体的治疗癌症的小分子疗法。公司的开发方式转换了相关癌症转换成药物，这些药物能够有效的和高选择性的达到关键科学见解的预期目标。这些药物通常能够达到更高的目标任务和改善相关肿瘤的反应。 公司识别和优先考虑的目标有两种方式。首先，该公司使用的临床试验数据来评估药物的发展，响应信号和识别那些承诺也证明药物的具体限制，如吸收差，差的分布或有害的副作用。第二，该公司评估学术研究发现新的目标与新兴的验证。一旦确定目标,公司使用先进的第三方技术来开发候选产品旨在增强目标接触和特异性。","exchange":"NASDAQ","name":"Loxo Oncology","nameEN":"Loxo Oncology"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"LOXO\",market:\"US\",,,undefined,":null}}